Results 71 to 80 of about 72,745 (302)

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases

Pediatric Rheumatology Online Journal, 2019
Background Despite the increased use of rituximab in treating pediatric patients with autoimmune diseases in the last decade, there are limited data on rituximab safety in those subjects who have a developing immune system. The objective of this study is
Amer M. Khojah, Michael L. Miller, Marisa S. Klein-Gitelman, Megan L. Curran, Victoria Hans, Lauren M. Pachman, Ramsay L. Fuleihan   +6 more
doaj   +1 more source

Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia. [PDF]

EBioMedicine, 2018
Ferrer G.
europepmc   +4 more sources

A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: Monitoring of testosterone replacement therapy with testosterone buciclate [PDF]

, 1998
Monitoring of testosterone replacement therapy requires a reliable method for testosterone measurement. Determination of salivary testosterone, which reflects the hormone's biologically active plasma fraction, is a superior technique for this purpose ...
Bals-Pratsch M, Blight LF, Dabbs, Ferguson DB, Meulenberg EP, Osredkar J, Pardridge WM, Schramm W, Schürmeyer T, Smith RG, Soini E, Strasburger CJ, Swinkels LM, Swinkels LM   +13 more
core   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease

Therapeutics and Clinical Risk Management, 2009
Suzanne Skoda-Smith, Troy R Torgerson, Hans D OchsSeattle Children’s Research Institute and Department of Pediatrics, University of Washington, Seattle, WashingtonAbstract: Antibody deficiency is the most frequently encountered primary ...
Suzanne Skoda-Smith, Troy R Torgerson, Hans D Ochs   +2 more
doaj  

COVID‐19 infection in CVID patients: What we know so far

Immunity, Inflammation and Disease, 2021
Introduction In patients with common variable immunodeficiency (CVID), immunological response is compromised. Knowledge about COVID‐19 in CVID patients is sparse. We, here, synthesize current research addressing the level of threat COVID‐19 poses to CVID
Niels Weifenbach, Alisha Jung, Stefan Lötters   +2 more
doaj   +1 more source

Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy [PDF]

Clinical and Experimental Immunology, 2017
SummaryImmunoglobulin replacement therapy enhances survival and reduces infection risk in patients with agammaglobulinaemia. We hypothesized that despite regular immunoglobulin therapy, some patients will experience ongoing respiratory infections and develop progressive bronchiectasis with deteriorating lung function.
A Stubbs, C Bangs, B Shillitoe, J D Edgar, S O Burns, M Thomas, H Alachkar, M Buckland, E McDermott, G Arumugakani, M S Jolles, R Herriot, P D Arkwright   +12 more
openaire   +6 more sources

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?

Frontiers in Immunology, 2018
BackgroundA significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen.
Philipp Scheuerlein, Larissa Pietsch, Nadezhda Camacho-Ordonez, Nadezhda Camacho-Ordonez, Veronika Reiser, Smita Patel, Siobhan O. Burns, Klaus Warnatz, Bodo Grimbacher, Bodo Grimbacher   +9 more
doaj   +1 more source